Fig. 2
From: Pim1 inhibition as a novel therapeutic strategy for Alzheimer’s disease
Pharmacological profile of Pim1i. a Chemical structure of the Pim1 inhibitor (Pim1i) used in this study. b The Pim1i levels measured in plasma as a function of time after a single intraperitoneal injection of 50 mg/kg. The maximum plasma concentration of Pim1i was 32166 ± 11220 ng/mL observed at 1 h post dose with half-life of 1.02 h. c Pim1i measured in the brain as a function of time after a single intraperitoneal injection of 50 mg/kg. Pim1i was also detectable up to 3 h post dose in brain tissue homogenate samples. The maximum brain concentration of 197 ± 48.5 ng/g was observed at 0.5 h post dose. d Pim1i reduced phosphorylated PRAS40 levels up to 24 h after a single intraperitoneal injection of 100 mg/kg. e Schematic of the experimental design. NonTg and 3xTg-AD mice were injected with either the vehicle or 100 mg/kg Pim1i for 28 days. All animals started behavioral testing in the radial arm water maze task at day 26